AI-Powered Prognosis Tracking Set to Revolutionize Cancer Patient Care
Table of Contents
Seoul, South Korea – A new collaboration between Seoul St. Mary’s Hospital, Digital Farm Co., Ltd., and InBody Healthcare Co., Ltd. promises to transform cancer patient care through continuous, real-time monitoring and analysis of patient health data. The partnership, formalized through a memorandum of understanding (MOU) signed on Thursday, August 8th, aims to develop and implement a cutting-edge cancer patient prognosis tracking service.
Bridging the Gap in Post-Treatment Monitoring
Historically, a significant challenge in cancer care has been the difficulty in consistently tracking a patient’s condition after treatment. Patients have faced limitations in effectively communicating changes to their medical teams, while clinicians have struggled to maintain a comprehensive, real-time understanding of patient status. This new initiative directly addresses these issues by creating a more connected and proactive system.
“This MOU will serve as an opportunity to implement a patient-centered continuous management system,” stated a senior official at Seoul St. Mary’s Hospital. “It will be the starting point for providing safer and more efficient medical care by detecting risk signals early and providing customized interventions.”
‘Dr. Answer 3.0’ and the Power of Home-Based Monitoring
The project centers around the development of a key disease prognosis management service, dubbed ‘Dr. Answer 3.0,’ with initial focus on breast cancer and kidney cancer. This represents a major step forward in the broader ‘Doctor Answer 3.0’ project, which encompasses ten key diseases. A core component of the system involves utilizing a specialized body composition measuring device designed for at-home use.
This device will evaluate crucial biomarkers, including resistance value (impedance) and extracellular water secretion in various body parts, such as the arms and legs. This detailed analysis will enable the early detection of conditions like lymphedema in breast cancer patients and fluid imbalance in those battling kidney cancer.
CaMEDIA: An AI-Driven Early Warning System
Data collected from the device, combined with self-reported symptoms from patients, will be integrated into CaMEDIA, a dedicated prognosis management app. This app is designed to act as an early warning system, identifying potential complications after surgery – such as swelling, weight change, and worsening nutritional status – before they escalate.
The app leverages artificial intelligence to automatically identify high-risk groups and provide real-time tracking and management tools for medical staff. This targeted approach is expected to significantly improve the efficiency of treatment centers.
A Precedent for Digital Healthcare Expansion
The collaboration’s success could establish a valuable empirical model for digital healthcare, potentially extending beyond cancer to encompass a wider range of diseases and healthcare systems. The three organizations will collaborate on key areas, including linking equipment data with medical records, developing data interpretation services, and rigorously verifying data-based cancer patient prognosis management services.
“This cooperation is an important starting point in establishing empirical evidence that everyday prognosis management services can improve actual treatment results,” explained a representative from Digital Farm. “We will do our best to ensure that the development of the Dr.Answer 3.0 prognosis management service contributes to the continuity and stability of patient treatment and presents the possibility of new future medical care.”
Hajin Park, CEO of InBody Healthcare, added, “We will contribute to collecting good data for practical results that detect changes in prognosis early and help medical staff quickly intervene.”
CaMEDIA and the associated services are currently undergoing verification and are slated for official launch in September 2026. This innovative approach to cancer care promises a future where proactive monitoring and personalized interventions become the standard, ultimately improving outcomes and quality of life for patients.
